|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||61.97 - 62.84|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||24.48|
|Earnings Date||Jan 24, 2018 - Jan 29, 2018|
|Forward Dividend & Yield||1.60 (2.58%)|
|1y Target Est||63.82|
Ringing today's closing bells are Giovanni Caforio, chairman & CEO of Bristol-Myers Squibb, at the NYSE and Draper Oakwood Technology Acquisition, Inc. with Tim Draper, founder of Draper Associates, at the Nasdaq.
Bristol-Myers (BMY) supplemental Biologics License Application (sBLA) for Opdivo and Yervoy combination for the treatment of intermediate- and poor-risk patients with advanced renal cell carcinoma was accepted by the FDA.
Orencia, Bristol-Myers Squibb’s (BMY) only immunoscience product, is a fusion protein approved for the treatment of moderate-to-severe rheumatoid arthritis and related issues. The drug prevents further ...
Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes Eliquis, one of the company’s largest selling products. The chart below shows Eliquis revenue over the last few quarters. Eliquis is a drug ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Bristol-Myers Squibb Co.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.
Bristol-Myers Squibb’s (BMY) virology portfolio includes hepatitis B , hepatitis C, and HIV products. The chart below compares revenue for each product category over the last few quarters. Baraclude, the ...
Bristol Myers Squibb’s (BMY) Opdivo is approved for the treatment of non-small cell lung cancer, classical Hodgkin’s lymphoma, renal cell carcinoma, metastatic melanoma, squamous cell carcinoma of the ...
Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue. The above ...
Bristol-Myers Squibb (BMY) reported EPS (earnings per share) of $0.75 in 3Q17, missing analysts’ estimate of $0.77. However, it surpassed their revenue estimate of $5.2 billion, reporting revenue of $5.3…...
Headquartered in New York City, pharmaceutical giant Bristol-Myers Squibb (BMY) offers various cardiovascular, immunoscience, neuroscience, oncology, and virology products.
Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced an agreement that grants Bristol-Myers Squibb an exclusive license for the development and commercialization of ONO-4578, Ono’s selective Prostaglandin E2 receptor 4 antagonist.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for priority review of Opdivo plus Yervoy to treat intermediate- and poor-risk patients with advanced renal cell carcinoma .
Bristol-Myers Squibb Company (BMY) announced positive data from an ongoing phase II study on leukemia drug Sprycel in addition to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone for two years.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Bristol-Myers Squibb Co. Here are 5 ETFs with the largest exposure to BMY-US. Comparing the performance and risk of Bristol-Myers Squibb Co. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.
Bristol-Myers Squibb Company (NYSE:BMY) maintained its current share price over the past couple of month on the NYSE, with a relatively tight range of $59.94 to $65.35. However, does thisRead More...
The S&P 500 Index largely treaded water last week as investors digested U.S. tax reform uncertainty and perhaps took some profits off the table as 2017 draws to a close. While stock prices generally didn’t do much, a number of companies announced higher dividends as a sign of confidence in their outlooks.
Seattle Genetics, Inc. and Bristol-Myers Squibb Company today highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS and Opdivo in relapsed or refractory classical Hodgkin lymphoma at the 59th American Society of Hematology Annual Meeting and Exposition taking place in Atlanta, Georgia, December 9-12, 2017.
Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.
Bristol-Myers Squibb Company today announced data from the phase 2 CA180-372 study in pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Sprycel added to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone.
Sandra Leung, now in her tenth year as Bristol-Myers Squibb’s general counsel, recently made a stunningly large stock sale. On Monday Dec. 4, Leung exercised options for 156,582 Bristol-Myers (BMY) shares and sold an equal number for more than $9.9 million, or $63.37 a share. Leung’s latest sale is the largest in one day since former CEO Lamberto Andreotti sold 235,000 shares in May 2016 for $16.9 million.